Novartis to keep making malaria drugs if orders dry up amid aid cuts
Ensuring availability of life-saving medicines
The company makes 28 million malaria treatment courses every year, and sells almost all of them a not-for-profit price to countries and groups including the President's Malaria Initiative (PMI), a U.S.-government funded initiative that still has an unclear future given President Donald President Trump's vast international aid cuts, although it did receive an exemption for some work earlier this year because of its lifesaving potential.
"We are not going to be the bottleneck," said Lutz Hegemann, president, Global Health and Sustainability, Novartis, in an interview. "We are not going to produce based on demand, because we know that these medicines are needed, and we need to be creative in finding ways to get them from the factory to patients."
Earlier this year, an order was cancelled by a contractor for PMI when it got a stop-work order from the U.S. government, Dr. Hegemann said. But then within a month it got an exception and asked for work to begin again.
"You cannot do that essentially in real-time. We remain committed to our volume," said Dr. Hegemann, adding that this also applied for leprosy, which it donates in smaller quantities through the World Health Organization (WHO).
Funding gap and
The Global Fund to Fight AIDS, TB and Malaria is the biggest buyer of Novartis' antimalarials. It has not yet faced cuts but is fundraising now for its future work in a difficult climate.
Speaking in London, Hegemann also urged the pharmaceutical sector to step up while governments, including the U.S., United Kingdom and France, pull back from aid funding, and particularly work more directly with governments that have traditionally been recipients of aid.
"I think it would be a missed opportunity if we just tried to essentially plug the gap that donor country funding has created, and I think we need to move beyond that," he said, pointing to public-private partnerships between pharmaceutical companies and low and middle-income countries as a model.
Dr. Hegemann also said Novartis is set to spend almost double what it pledged to by the end of 2025 on malaria and neglected tropical diseases research and development: $490m rather than its pledged $250m. Products in development include a dengue antiviral, new treatments for leishmaniasis and Chagas disease, and the first malaria treatment for newborn babies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
India's Apollo Hospitals to double AI investments, beats profit estimate
Hyderabad: India's Apollo Hospitals Enterprise plans to double its investment in artificial intelligence capabilities over the next two to three years, its CEO said, after the company beat first-quarter profit estimates on higher patient volume. The hospital chain already uses AI tools in diagnosis to read X-rays, scan reports and also in endoscopy - a medical procedure to examine the inside of the body using a camera, CEO Madhu Sasidhar told Reuters on Tuesday. Many large private hospital chains in India, like their western counterparts, are investing in AI capabilities to improve patient diagnosis and decisions related to medical procedures, among others uses. Apollo recently developed technology to read existing scan reports and predict the risk of liver fibrosis in the future, Sasidhar said. "We are also bringing some other new generation agentic AI-type tools," he said. He did not quantify the size of Apollo's existing investment in AI. Apollo, headquartered in the south Indian city of Chennai, partnered with Microsoft earlier this year to develop AI-based tools to be used in healthcare. Some of them are in early stages of testing, Sasidhar said. Indian hospital chains such as Apollo and Manipal have also been increasing their bed count for a larger share of the market, including through acquisitions of smaller hospital operators. Apollo said it is on track to add 4,370 beds over the next 3-4 years through acquisition, new hospitals and expansion of existing facilities. Its overall bed capacity is currently more than 10,000. The company's consolidated net profit rose 41.8% to 4.33 billion rupees ($49.40 million) for April-June, beating estimates of 3.86 billion rupees, according to data compiled by LSEG. While its overall occupancy rate dipped from last year, in-patient volume grew 3% and average revenue per in-patient increased by 9%, according to Apollo. Quarterly total revenue rose 15% to 58.42 billion rupees, beating estimates of 57.44 billion rupees. The company said it expects double-digit revenue growth for the current financial year.
Hindustan Times
13 hours ago
- Hindustan Times
RFK Jr. unveils ‘wholesome meal' initiative for $4 cheaper than Big Mac, netizens say ‘not easy'
US Health Secretary Robert F. Kennedy Jr. announced that the Trump administration is in discussions to expand the distribution of a 'very wholesome meal for under $5' to underprivileged communities. Kennedy's public health strategy under the Trump administration has focused heavily on the fight against ultra-processed foods. (Reuters) Kennedy's public health strategy under the Trump administration has focused heavily on the fight against ultra-processed foods. Kennedy has called these foods 'poison,' and he has stressed their significance in America's chronic disease epidemic, particularly among disadvantaged groups. It is still quite difficult to find reasonably priced, healthful food in many disadvantaged regions, which are referred to as 'food deserts.' The prevalence of diet-related diseases like diabetes is higher in these places, placing a burden on both public health systems and people. Healthy American diets are essential to Kennedy's goal of 'Make America Healthy Again.' While unveiling a new public health initiative on Monday, he has promised a move away from corporate profit incentives toward real health advances, particularly in marginalized communities. Also Read: What is the reason behind Ashley Biden's divorce from Dr Howard Krein? 'New life, new beginnings…' RFK Jr's reveals plan to provide wholesome meal Speaking to Scripps News, the US Health Secretary stated, 'We're going to launch a new rubric where we, the public health agencies, actually do public health rather than promoting the profit taking by private corporations. And there's some parts though in some underserved communities, there are food deserts where people don't have access to some of these foods. And if they do, sometimes it's too expensive.' Kennedy recognized the challenges in reaching lower socioeconomic groups, but he stressed that 'cheap food is an illusion.' 'If you say this food is cheap and you get diabetes from it, is it really cheap? We're working all over the country in food deserts,' he said. 'We're working with private corporations that are providing good meals. We looked at one company that we met with recently that can provide a very, very wholesome meal for under $5. A Big Mac costs, I think, $9 now,' Kennedy continued. 'You can get high-quality food as we change these rules to incentivize people to buy better food. You're going to see the markets respond, and you're going to see better food going into these food deserts,' he added. What we know about Big Mac meal According to McDonald's, the average cost of a Big Mac meal in the US in 2024 was approximately $9.29, whereas a Big Mac alone costs $5.29. However, costs may differ depending on where you are. According to Tasting Table, the price of a Big Mac may range from $8.69 in some places, such as New York, to less in other places. Internet reacts to RFK Jr's plan While Kennedy made no mention of the meals or the businesses that would produce them, several netizens were quick to react on his proposed plan. 'Would love to see exact details on the company and its food products. If they are actually good quality, this would be revolutionary for places around the country,' one X user wrote. 'Great idea! I wish there were grants for cooking classes and food trucks to roam the poorest streets throwing out fresh fruits for all!' another said. 'One of the most important things that needs to happen is fixing food deserts. Praying he can get this done. Not easy,' a third person stated.
Time of India
13 hours ago
- Time of India
Medical journal rejects Kennedy's call for retraction of vaccine study
London: An influential U.S. medical journal is rejecting a call from Health Secretary Robert F. Kennedy Jr. to retract a large Danish study that found that aluminum ingredients in vaccines do not increase health risks for children, the journal's editor told Reuters. Kennedy has long promoted doubts about vaccines' safety and efficacy, and as health secretary has upended the federal government's process for recommending immunization. A recent media report said he has been considering whether to initiate a review of shots that contain aluminum, which he says are linked to autoimmune diseases and allergies. The study, which was funded by the Danish government and published in July in the Annals of Internal Medicine , analyzed nationwide registry data for more than 1.2 million children over more than two decades. It did not find evidence that exposure to aluminum in vaccines had caused an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders. The work is by far the best available evidence on the question of the safety of aluminum in vaccines, said Adam Finn, a childhood vaccination expert in the UK and pediatrician at the University of Bristol, who was not involved in the study. "It's solid, (a) massive dataset and high-quality data," he said. Kennedy described the research as "a deceitful propaganda stunt by the pharmaceutical industry," and said the scientists who authored it had "meticulously designed it not to find harm" in a detailed Aug. 1 opinion piece on TrialSite News, an independent website focused on clinical research. He called on the journal to "immediately retract" the study. "I see no reason for retraction," Dr. Christine Laine, editor in chief of the Annals and a professor of medicine at Thomas Jefferson University, said in an interview. The journal plans to respond to criticism the article has received on its website, Laine said, but it does not intend to respond directly to Kennedy's piece, which was not submitted to the Annals. The lead author of the study, Anders Peter Hviid, head of the epidemiology research department at the Statens Serum Institut in Denmark, defended the work in a response post to TrialSite. He wrote that none of the critiques put forward by Kennedy were substantive and he categorically denied any deceit as implied by the secretary. "I am used to controversy around vaccine safety studies - especially those that relate to autism, but I have not been targeted by a political figurehead in this way before," Hviid said in an emailed response to Reuters. "I have confidence in our work and in our ability to reply to the critiques of our study." Kennedy had a number of critiques, including the lack of a control group, that the study deliberately excluded different groups of children to avoid showing a link between aluminum and childhood health conditions - including those with the highest levels of exposure - and that it did not include the raw data. Hviid responded to the criticisms on TrialSite. He said some of the points were related to study design choices that were reasonable to discuss but refuted others, including that the study was designed not to find a link. In fact he said, its design was based on a study led by Matthew Daley, a pediatrician at Kaiser Permanente Colorado, which did show a link, and which Kennedy cited in his article. There was no control group because in Denmark, only 2% of children are unvaccinated, which is too small for meaningful comparison, Hviid added. The data is available for researchers to analyze, but individual-level data is not released under Danish law, he said. Other prominent vaccine skeptics including those at the antivaccine organization Kennedy previously ran, Children's Health Defense, have similarly criticized the study on the Annals site. TrialSite staff defended the study for its scale, data transparency and funding while acknowledging the limitations of its design, a view seconded by some outside scientists. Laine said that while some of the issues Kennedy raised in his article may underscore acceptable limitations of the study, "they do not invalidate what they found, and there's no evidence of scientific misconduct."
